Bifogade filer
Lipidor provides update following outcome of Phase III study of psoriasis candidate AKP02
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
STOCKHOLM, 15 November 2022 – On October 28, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced that the Phase III study with the combination preparation AKP02 did not achieve the criterion of equivalent therapeutic efficacy in the treatment of psoriasis compared to the market-leading reference product. However, the study results show that AKP02 has good efficacy in comparison with placebo and there is support for claiming efficacy on par with other psoriasis products. The company's assessment is that AKP02 still has significant potential and the goal is to continue to realize that value. Intensive work is underway to investigate the conditions for this, which includes strategy and financing.
Initial dialogue has been conducted with the company’s commercial partner RELIFE, a company in the Menarini Group, which has taken note of Lipidor’s conclusion that both the AKVANO® technology and the specific formulation work and furthermore stand up well in comparison with other psoriasis products. Discussions are at an early stage and include regulatory and market considerations.
The Lipidor Board of Directors is now investigating various options to finance the company's continued operations and continued work on AKP02. It remains the board's opinion that the company's project portfolio includes several programs with significant market potential and thus great value. Among other things, this applies to the program in the acne area and other projects where the company has or is looking for partners. It is also noted that Lipidor's subsidiary Emollivet, which has launched products for the treatment of skin conditions in animals, is developing in a positive way and shows that AKVANO® technology is extremely well-suited for these applications.
“With the study results, our position is that the drug candidate AKP02 compares well with several existing preparations on the market,” says the company's CEO, Ola Holmlund. “We work with a solution-oriented, fact-based approach, and remain optimistic. Intensive internal work is underway on strategy, business plan, costs and financing to take advantage of the company's opportunities and value in the best way.”
Publication
This information was provided for publication by Lipidor’s CEO on 15 November 2022 at 8.00am CET.